CeriBell reported second quarter 2026 financial results with total revenue of $28.1 million, a 33% increase from the prior year period. The company achieved a gross margin of 92%, driven by manufacturing cost reductions and tariff refunds, while operating expenses rose to $45.9 million due to commercial expansion and intellectual property litigation costs. Net loss widened to $19.3 million, or $0.51 per share, compared to $13.6 million in the same period last year. CeriBell secured a new credit facility providing up to $60 million in committed capital and raised its full-year 2026 revenue guidance to $114–$117 million. The company also received FDA clearances for new algorithms and hardware designs, as well as Medicare New Technology Add-On Payment for delirium monitoring. CeriBell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions through its point-of-care electroencephalography platform.

On July 28, 2026, CeriBell, Inc.'s Board rebalanced its director classes by re-electing William W. Burke to Class II and Joseph M. Taylor to Class III. The Board increased its authorized size from seven to nine directors and elected Sharon L. O’Keefe and Thomas A. West as new Class I directors. Each new director received an initial restricted stock unit award valued at $300,000 based on the average closing price over the prior 30 trading days. CeriBell develops medical devices for continuous electroencephalography monitoring.